Research map: JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study

Back to the article

Papers in this map

  1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk · François Mach · 2019 · 9168 citations · Cited by this paper
  2. JAK inhibitor-related AEs in patients with dermatitis or alopecia · 2026 · Cites this paper
  3. Consensus Recommendations for Management of Darier Disease: A Practical Approach · 2026 · Related
  4. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial · Eric Lawrence Simpson · 2020 · 515 citations · Cited by this paper
  5. Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy · 2026 · Related
  6. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis · Andrew Blauvelt · 2021 · 504 citations · Cited by this paper
  7. Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension · 2026 · Related
  8. Two Phase 3 Trials of Baricitinib for Alopecia Areata · Brett King · 2022 · 502 citations · Cited by this paper
  9. Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment · 2026 · Related
  10. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial · Kristian Reich · 2021 · 407 citations · Cited by this paper
  11. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo · 2026 · Related
  12. Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials · Eric Lawrence Simpson · 2020 · 393 citations · Cited by this paper
  13. Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study · 2026 · Related
  14. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial · Brett King · 2023 · 292 citations · Cited by this paper
  15. Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study · 2026 · Related
  16. Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies · Dawn Marie R. Davis · 2023 · 257 citations · Cited by this paper
  17. Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials · 2026 · Related
  18. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial · Kristian Reich · 2022 · 252 citations · Cited by this paper
  19. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region · 2026 · Related
  20. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study · Richard J. Silverwood · 2018 · 168 citations · Cited by this paper
  21. Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival · 2026 · Related
  22. Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program · Eric Lawrence Simpson · 2021 · 141 citations · Cited by this paper
  23. Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitors in Immune-Mediated Inflammatory Skin Diseases · Jenne P. Ingrassia · 2023 · 90 citations · Cited by this paper
  24. The safety of systemic Janus kinase inhibitors in atopic dermatitis: A systematic review and meta‐analysis of randomized controlled trials · Sanghyuk Yoon · 2023 · 72 citations · Cited by this paper
  25. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies · Emma Guttman‐Yassky · 2022 · 70 citations · Cited by this paper
  26. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program · Brett King · 2024 · 63 citations · Cited by this paper
  27. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials · Brett King · 2022 · 60 citations · Cited by this paper
  28. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure · Eric Lawrence Simpson · 2024 · 58 citations · Cited by this paper
  29. Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study · Serena Yun‐Chen Tsai · 2024 · 54 citations · Cited by this paper
  30. Noncutaneous and Cutaneous Cancer Risk in Patients With Atopic Dermatitis · Lily Hui-Ching Wang · 2019 · 53 citations · Cited by this paper
  31. Malignancy risk in patients with atopic dermatitis: a population-based cohort study · Joy Y. Wan · 2023 · 52 citations · Cited by this paper
  32. Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications · Peter Charles Taylor · 2023 · 42 citations · Cited by this paper
  33. The safety of systemic Janus kinase inhibitors in atopic dermatitis: a systematic review and network meta-analysis · Carlos Alves · 2022 · 35 citations · Cited by this paper
  34. Infection risk in atopic dermatitis patients treated with biologics and JAK inhibitors: BioDay results · Lian F. van der Gang · 2025 · 34 citations · Cited by this paper
  35. Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis · Cécile Ertus · 2023 · 25 citations · Cited by this paper
  36. Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review · Andrea Sechi · 2023 · 23 citations · Cited by this paper
  37. Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis · Jawad Bilal · 2021 · 20 citations · Cited by this paper
  38. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses · Qingying He · 2024 · 19 citations · Cited by this paper
  39. Potential role of leptin in Janus kinase 2 inhibitor-associated weight gain: a monocentric retrospective study · Luciano Ibba · 2025 · 18 citations · Cited by this paper

Source: OpenAlex (CC0)